NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
9.72
+1.24 (14.62%)
Sep 10, 2025, 2:59 PM - Market open

Company Description

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.

Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors.

The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.

NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is headquartered in Calabasas, California.

NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings logo
CountryUnited States
Founded2008
IndustryBiotechnology
SectorHealthcare
Employees8
CEOThomas Chen

Contact Details

Address:
23975 Park Sorrento, Suite 205
Calabasas, California 91302
United States
Phone310-663-7831
Websiteneonc.com

Stock Details

Ticker SymbolNTHI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001979414
ISIN NumberUS64051A1016
Employer ID92-1954864
SIC Code2834

Key Executives

NamePosition
Dr. Thomas C. Chen M.D., Ph.D.Founder, Chief Executive Officer, Chief Scientific Officer and Director
Keithly A. GarnettChief Financial Officer and Director
Amir Farrokh HeshmatpourPresident, Executive Chairman and Secretary
Dr. Josh Neman-Ebrahim Ph.D.Chief Clinical Officer

Latest SEC Filings

DateTypeTitle
Aug 22, 20258-KCurrent Report
Aug 20, 20258-K/A[Amend] Current report
Aug 18, 202510-QQuarterly Report
Aug 18, 20258-KCurrent Report
Aug 14, 2025NT 10-QNotification of inability to timely file Form 10-Q or 10-QSB
Aug 13, 20258-KCurrent Report
Aug 1, 20258-KCurrent Report
Jul 30, 20258-KCurrent Report
Jul 25, 20258-KCurrent Report
Jul 22, 20258-KCurrent Report